Pacific Biosciences Of California (PACB) Return on Capital Employed (2011 - 2026)
Pacific Biosciences Of California (PACB) posted quarterly Return on Capital Employed of 18.57% for Q1 2026, up 6412.0% year-over-year from 0.29% in Q1 2025, and up 75.84% quarter-over-quarter from 76.84% in Q4 2025.
Pacific Biosciences Of California (PACB) Return on Capital Employed (2011 - 2026) Analysis & Trends
Pacific Biosciences Of California's Return on Capital Employed history runs 16 years deep, the most recent figure standing at 18.57% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 6412.0% year-over-year to 18.57%; the TTM figure through Mar 2026 stood at 18.57% (up 6412.0% YoY), while the FY2025 annual figure was 58.34%, down 2533.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 18.57%, up from 76.84% in the prior quarter.
- The five-year high for Return on Capital Employed was 11.17% in Q1 2022, with the low at 88.63% in Q3 2025.
- The 5-year median for Return on Capital Employed is 20.38% (2023), against an average of 35.86%.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed sank 6283 bps in 2025, then soared 6412 bps in 2026.
- Pacific Biosciences Of California's Return on Capital Employed stood at 20.08% in 2022, then advanced by 4 bps to 19.37% in 2023, then slumped by 90 bps to 36.8% in 2024, then sank by 109 bps to 76.84% in 2025, then surged by 76 bps to 18.57% in 2026.
- Business Quant data shows PACB's Return on Capital Employed at 18.57% in Q1 2026, 76.84% in Q4 2025, and 88.63% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.24 Bn | 193.64 Bn | 7.27 Bn | 7.98% |
| 2 | Stryker | 128.63 Bn | 125.15 Bn | 4.50 Bn | 13.69% |
| 3 | Medtronic | 119.19 Bn | 109.97 Bn | 6.41 Bn | 8.02% |
| 4 | Boston Scientific | 73.51 Bn | 72.97 Bn | 3.85 Bn | 10.83% |
| 5 | Edwards Lifesciences | 52.11 Bn | 47.85 Bn | 1.35 Bn | 11.99% |
| 6 | Dexcom | 34.64 Bn | 32.70 Bn | 830.00 Mn | 27.21% |
| 7 | GE HealthCare Technologies | 34.01 Bn | 31.90 Bn | 2.18 Bn | 9.47% |
| 8 | Koninklijke Philips | 26.40 Bn | 23.08 Bn | 4.55 Bn | 12.84% |
| 9 | Steris | 23.14 Bn | 22.65 Bn | 684.20 Mn | 12.08% |
| 10 | Pacific Biosciences Of California | 398.57 Mn | 161.70 Mn | 12.64 Mn | -19.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19.05% |
| Mar 31, 2026 | -18.57% |
| Dec 31, 2025 | -76.84% |
| Sep 30, 2025 | -88.63% |
| Jun 30, 2025 | -88.19% |
| Mar 31, 2025 | -82.68% |
| Dec 31, 2024 | -36.80% |
| Sep 30, 2024 | -28.80% |
| Jun 30, 2024 | -28.27% |
| Mar 31, 2024 | -19.85% |
| Dec 31, 2023 | -19.37% |
| Sep 30, 2023 | -19.77% |
| Jun 30, 2023 | -20.38% |
| Mar 31, 2023 | -20.49% |
| Dec 31, 2022 | -20.08% |
| Sep 30, 2022 | -16.13% |
| Jun 30, 2022 | -13.60% |
| Mar 31, 2022 | -11.17% |
| Dec 31, 2021 | -17.14% |
| Jun 30, 2021 | -9.92% |